Statin use and cancer risk in the General Practice Research Database

Por Kaye, J A, Jick, H
Publicado em 2004

Statin use, hyperlipidaemia, and the risk of breast cancer

Por Kaye, J A, Meier, C R, Walker, A M, Jick, H
Publicado em 2002

Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline

Por Silbert, L C., Nelson, C, Howieson, D B., Moore, M M., Kaye, J A.
Publicado em 2008

In-home walking speeds and variability trajectories associated with mild cognitive impairment

Por Dodge, H.H., Mattek, N.C., Austin, D., Hayes, T.L., Kaye, J.A.
Publicado em 2012

The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data

Por Kaye, J A, Derby, L E, Melero-Montes, M del Mar, Quinn, M, Jick, H
Publicado em 2000

Unobtrusive assessment of activity patterns associated with mild cognitive impairment

Por Hayes, T.L., Abendroth, F., Adami, A., Pavel, M., Zitzelberger, T.A., Kaye, J.A.
Publicado em 2008

Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance

Por Bowman, G.L., Kaye, J.A., Moore, M., Waichunas, D., Carlson, N.E., Quinn, J.F.
Publicado em 2007

Neuropathological basis of age-associated brain atrophy

Por Erten-Lyons, D., Dodge, H. H., Woltjer, R., Silbert, L.C., Howieson, D.B., Kramer, P., Kaye, J. A.
Publicado em 2013

Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures

Por Promjunyakul, N., Lahna, D., Kaye, J.A., Dodge, H.H., Erten-Lyons, D., Rooney, W.D., Silbert, L.C.
Publicado no Neuroimage Clin (2015)

Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease.

Por Schapiro, M B, Pietrini, P, Grady, C L, Ball, M J, DeCarli, C, Kumar, A, Kaye, J A, Haxby, J V
Publicado em 1993

Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging

Por Bowman, G.L., Silbert, L.C., Howieson, D., Dodge, H.H., Traber, M.G., Frei, B., Kaye, J.A., Shannon, J., Quinn, J.F.
Publicado em 2012

Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women.

Por Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., Bird, T. D., Yu, C. E., Wijsman, E. M., Heston, L. L., Litt, M., Schellenberg, G. D.
Publicado em 1996

A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q.

Por Harrison, G A, Humphrey, K E, Jones, N, Badenhop, R, Guo, G, Elakis, G, Kaye, J A, Turner, R J, Grehan, M, Wilton, A N, Brennecke, S P, Cooper, D W
Publicado em 1997

ADAM10 Expression and Promoter Haplotype in Alzheimer’s Disease

Por Bekris, L.M., Lutz, F., Li, G., Galasko, D.R., Farlow, M.R., Quinn, J.F., Kaye, J.A., Leverenz, J.B., Tsuang, D.W., Montine, T.J., Peskind, E.R., Yu, C.E.
Publicado em 2012

APP Processing Genes and Cerebrospinal Fluid APP Cleavage Product Levels in Alzheimer’s Disease

Por Bekris, L.M., Galloway, N.M., Millard, S., Lockhart, D., Li, G., Galasko, D.R., Farlow, M.R., Clark, C.M., Quinn, J.F., Kaye, J.A., Schellenberg, G.D., Leverenz, J.B., Seubert, P., Tsuang, D.W., Peskind, E.R., Yu, C.E.
Publicado em 2010

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

Por Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., Clark, C. M., Fagan, A. M., Galasko, D. R., Holtzman, D. M., Jutel, M., Kaye, J. A., Lemere, C. A., Leszek, J., Li, G., Peskind, E. R., Quinn, J. F., Yesavage, J. A., Ghiso, J. A., Wyss-Coray, T.
Publicado em 2009